Regulus Therapeutics, the microRNA joint venture between Alnylam Pharmaceuticals and Isis Pharmaceuticals, this week announced that it has appointed Stelios Papadopoulos to its board of directors.
Stelios Papadopoulos
Premium
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.